黄芪治疗小儿呼吸道反复感染的作用机理及剂型的研究进展  

Progress of Astragalus in New Forms and Its Treatment for Recurrent Infection of Respiratory Tract in Children

作　　者：童宁[1] 

机构地区：[1]南京市第二医院药剂科,南京210046

出　　处：《药学与临床研究》2012年第5期430-434,共5页Pharmaceutical and Clinical Research

摘　　要：小儿反复呼吸道感染的治疗一直以干扰素为主,其副作用大,尤其对肝脏伤害大,黄芪的治疗效果已经得到证实,且副作用小,成本低,拥有更广泛的市场前景。本文综述了黄芪对防治小儿反复呼吸道感染的机制与临床应用比较,重点阐述了黄芪新剂型的制备及研究的进展。建议在用黄芪治疗小儿反复呼吸道感染时注重剂型的选择,以便更能符合治疗需求。Treatment of recurrent respiratory tract infections in children has been dominated by interferons.Its side effects are severe,and it hurts especially the liver.Effect of Astragalus has been confirmed that it has mild side effects,low costs and broad market prospects.This article summarized acting mechanism and clinical application in recurrent respiratory tract infections,focusing on the preparation and research progress of new Astragalus dosage forms.We propose that in curing recurrent respiratory tract infection of children with Astragalus,attention should be payed to the selection of dosage form in order to better meet the demand of treatment.

关 键 词：小儿呼吸道反复感染 剂型 研究进展 

分 类 号：R285[医药卫生—中药学] R944[医药卫生—中医学]